Ana Molina

Ana Molina

Auto-generated profile, based on publicly available information

Ana Molina

Weill Cornell Medicine 1 Division of Hematology & Medical Oncology, Department of Medicine New York, New York

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in European Journal of Cancer
Verified
Journal Article
Open access
AMAna M. Molina
Ana M. Molina
Thomas HutsonThomas Hutson
Thomas Hutson
DNDmitry Nosov
Dmitry Nosov
PTPiotr Tomczak
Piotr Tomczak
OLOleg Lipatov
Oleg Lipatov
TETim Eisen
Tim Eisen
Tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2 and 3 tyrosine kinases. This open-label, crossover clinical study (AV-951-09-902) provided access to tivozanib for patients who progressed on sorafenib in TIVO-1, comparing tivozanib with sorafenib in patients with advanced renal cell carcinoma (RCC). Patients enrolled in this single-arm, phase 2 crossover study were previously randomised to sorafenib on TIVO-1, progressed and then crossed over to tivozanib. Patients received tivozanib (1.5 mg/day orally; 3 weeks on/1 week off) within 4 weeks after their last sorafenib dose. Crossover patients were exposed to tivozanib for a median of eight cycles. From the start of tivozanib treatment, median progression-free survival was 11.0 months (95% confidence interval [CI]: 7.3-12.7) and median overall survival was 21.6 months (95% CI: 17.0-27.6). Best overall response was partial response in 29 (18%) patients and stable disease in 83 (52%) patients, with a median duration of response of 15.2 and 12.7 months, respectively. About 77% of patients experienced adverse events, most frequently hypertension (26%), followed by diarrhoea (14%) and fatigue (13%); 53% of patients had treatment-related adverse events, including 24% grade ≥3. About 9% and 16% of patients had dose reductions and dose interruptions due to adverse events, respectively. A total of 30% of patients had serious adverse events, and 4% had treatment-related serious adverse events. This crossover study of patients with advanced RCC demonstrated potent tivozanib anti-tumour activity. Safety and tolerability profiles were acceptable and consistent with the established adverse event profile of tivozanib.

8 April 2015 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
ASAlexander Sankin
Alexander Sankin
AHA. Ari Hakimi
A. Ari Hakimi
JHJames J. Hsieh
James J. Hsieh
AMAna M. Molina
Ana M. Molina
Much progress has been made in the treatment of metastatic renal cell carcinoma (RCC) over the last decade, with the development of agents that block the vascular endothelial growth factor (VEGF) pathway or the mammalian target of rapamycin (mTOR) pathway. The incorporation of these agents into treatment algorithms has been the result of carefully conducted clinical trials leading to Food and Drug Administration (FDA) approval and subsequent adoption as the current standard of care. These trials, however, were dominated by patients with clear cell renal cell carcinoma (ccRCC), and little data is currently available on the treatment of non clear cell renal cell carcinoma (nccRCC). nccRCC encompasses a biologically heterogeneous group of kidney tumors that portend very diverse prognoses and responses to therapy. This review is a pathway based approach that highlights the current systemic treatment strategies for metastatic nccRCC.

3 January 2020 in Investigational New Drugs
Verified
Journal Article
Closed access
PDF file
AMAna M. Molina
Ana M. Molina
JMJohannes C. van der Mijn
Johannes C. van der Mijn
PCPaul Christos
Paul Christos
JWJohn Wright
John Wright
CTCharlene Thomas
Charlene Thomas
LGLorraine J. Gudas
Lorraine J. Gudas

20 May 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RMRobert Motzer
Robert Motzer
Thomas HutsonThomas Hutson
Thomas Hutson
HGHilary Glen
Hilary Glen
DMDror Michaelson
Dror Michaelson
AMAna M. Molina
Ana M. Molina
JLJames M. G. Larkin
James M. G. Larkin
4506 Background: Lenvatinib (LEN), an oral tyrosine kinase inhibitor of VEGFR1–3, FGFR1–4, PDGFRα, RET, and KIT, in combination with EVE had manageable toxicity and antitumor activity in a phase 1 mRCC trial (CCP 2013;73:181). This phase II, open-label, multicenter study compared LEN, EVE, and LEN+EVE in pts with mRCC. Methods: Pts with progressive clear cell mRCC following 1 VEGF-targeted therapy were randomized 1:1:1 to LEN (24 mg/d), EVE (10 mg/d), or LEN+EVE (18+5 mg/d) in 28d cycles. The primary objective was progression-free survival (PFS) of LEN+EVE or LEN vs EVE. Secondary objectives included overall survival (OS), objective response rate (ORR), and safety. Primary analysis data cutoff was June 13, 2014. Results: One hundred and fifty-three pts were enrolled: 99% had one prior VEGF-targeted therapy, 1% had two; 18% had prior immunotherapy. LEN+EVE prolonged PFS vs EVE (Table; hazard ratio [HR] 0.40; 95% confidence interval [CI] 0.24–0.68; P < 0.001). LEN alone also prolonged PFS vs EVE (HR 0.61; 9...

5 April 2022 in Molecular Oncology
Verified
Journal Article
Open access
JMJohannes C. van der Mijn
Johannes C. van der Mijn
KEKenneth W. Eng
Kenneth W. Eng
PCPooja Chandra
Pooja Chandra
EFEvan Fernandez
Evan Fernandez
SRSinan Ramazanoglu
Sinan Ramazanoglu
AMAna M. Molina
Ana M. Molina
Primary clear cell renal cell carcinoma (ccRCC) has been previously characterized, but the genomic landscape of metastatic ccRCC is largely unexplored. Here, we performed whole exome sequencing (WES) in 68 samples from 44 patients with ccRCC, including 52 samples from a metastatic site.SETD2,PBRM1,APCandVHLwere the most frequently mutated genes in the metastatic ccRCC cohort.RBM10andFBXW7were also among the 10 most frequently mutated genes in metastatic tissues. Recurrent somatic copy number variations (CNV) were observed at the previously identified regions 3p25, 9p21 and 14q25, but also at 6p21 (CDKN1A) and 13q14 (RB1). No statistically significant differences were found between samples from therapy‐naïve and pretreated patients. Clonal evolution analyses with multiple samples from 13 patients suggested that early appearance of CNVs at 3p25, 9p21 and 14q25 may be associated with rapid clinical progression. Overall, the genomic landscapes of primary and metastatic ccRCC seem to share frequent CNVs at 3p25, 9p21 and 14q25. Future work will clarify the implication ofRBM10andFBXW7mutations and 6p21 and 13q14 CNVs in metastatic ccRCC.

3 April 2017 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
PVPanagiotis Vlachostergios
Panagiotis Vlachostergios
AMA. M. Molina
A. M. Molina
A better understanding of the pathophysiology of renal cell carcinoma (RCC) on a molecular level has led to the development of new treatment strategies. The discovery of the von Hippel-Lindau (VHL) gene and its role in regulating pro-angiogenic factors, including vascular endothelial growth factor (VEGF), platelet-derived growth factor and others, have led to the development of targeted therapies. Multi-tyrosine kinase inhibitors (e.g. sunitinib, sorafenib, pazopanib, axitinib, cabozantinib and lenvatinib), the VEGF-A ligand antibody (bevacizumab) that blocks the VEGF pathway, as well as the mammalian target of rapamycin (mTOR) inhibitors (temsirolimus and everolimus) that block the mTOR pathway have emerged as powerful clinical tools in the management of advanced disease. These agents have been approved by the FDA based on a series of pivotal...